8-K: Vivos Therapeutics Boosts ATM Offering to $3.58M

Vivos Therapeutics, Inc. increased the aggregate offering price of its common stock under an At The Market offering agreement to up to $3,583,686.

Summary

• Vivos Therapeutics, Inc. (VVOS) filed a prospectus supplement on October 24, 2025, to increase the aggregate offering price of its common stock.
• The increase pertains to shares issuable pursuant to the At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., originally dated February 14, 2025.
• The company can now offer and sell up to $3,583,686 of common stock under this ATM facility.
• Ellenoff Grossman & Schole LLP provided a legal opinion confirming that the shares, when issued and paid for, will be validly issued, fully paid, and non-assessable.

Sentiment

Score: 6

Explanation: The filing indicates a positive step for capital access, but the potential for dilution from an increased ATM offering introduces a minor negative aspect. Overall, it's a neutral to slightly positive procedural update.

Positives

• Increased flexibility for Vivos Therapeutics to raise capital through its At The Market offering.
• The legal opinion confirms that the shares, when issued and paid for, will be validly issued, fully paid, and non-assessable, providing legal certainty for investors.

Negatives

• The increase in the ATM offering size suggests a potential for further dilution for existing shareholders as more shares may be issued.

Future Outlook

The company has increased its capacity to raise capital through its At The Market offering, providing enhanced flexibility for future financing needs.

Industry Context

At The Market (ATM) offerings are a common and flexible method for publicly traded companies to raise capital over time, often used to fund operations, strategic initiatives, or general corporate purposes without the immediate pricing pressure of a traditional underwritten offering. This move by Vivos Therapeutics aligns with typical corporate finance strategies for accessing public markets.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of additional common stock.
• Company: Enhanced financial flexibility and access to capital for general corporate purposes.

Next Steps

• The company may continue to offer and sell shares of its common stock under the At The Market Offering Agreement up to the increased aggregate offering price.

Key Dates

Recommendation

The filing is a procedural update regarding an existing At The Market (ATM) offering, increasing the maximum aggregate offering price. While it provides the company with greater flexibility to raise capital, it also introduces the potential for further shareholder dilution. This type of update typically does not warrant a change in investment thesis unless the capital raise is tied to specific, significant strategic developments or financial distress, which are not detailed here. Therefore, a 'hold' recommendation is appropriate as it maintains the current position while acknowledging the company's enhanced capital access and potential dilution.

Keywords

Vivos Therapeutics, VVOS, ATM Offering, Equity Offering, Common Stock, Prospectus Supplement, Capital Raise, SEC Filing, Form 8-K